Liquidia Technologies Inc

Stock Chart, Company Information, and Scan Results

$24.10(as of Aug 12, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Liquidia Technologies Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$24.10
Ticker SymbolLQDA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees170
CountyUSA
Market Cap$1,812.3M

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Liquidia Technologies Inc In Our Stock Scanner

As of Aug 13, 2025
example chart graphic
Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.